In the context of a Lanham Act case, CRA assessed whether market performance for a hospital-based pharmaceutical product was affected by alleged improper statements by a competitor. CRA’s causality analysis included consideration of other economic factors that affected product sales, including assessment of market preparation, launch, commercialization, and promotional efforts used to support the product that was allegedly affected by improper marketing support.
CRA experts win prestigious 2026 Antitrust Writing Awards
The awards recognize outstanding scholarship and advocacy in antitrust law and economics. Christian Michel, a principal in the Antitrust & Competition...